Immunome, Inc. (NASDAQ:IMNM) Receives $31.50 Consensus Price Target from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been given an average recommendation of “Buy” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.67.

A number of brokerages recently issued reports on IMNM. Guggenheim began coverage on shares of Immunome in a research note on Monday. They issued a “buy” rating and a $35.00 price target on the stock. Wedbush upped their price target on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research note on Monday, April 1st. Leerink Partnrs reiterated an “outperform” rating on shares of Immunome in a research note on Monday, January 29th. Finally, SVB Leerink began coverage on shares of Immunome in a research note on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target on the stock.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. TD Asset Management Inc purchased a new stake in shares of Immunome during the 3rd quarter valued at about $1,063,000. Acadian Asset Management LLC purchased a new stake in shares of Immunome during the 3rd quarter valued at about $414,000. Emfo LLC purchased a new stake in shares of Immunome during the 4th quarter valued at about $633,000. Dorsey Wright & Associates purchased a new stake in shares of Immunome during the 3rd quarter valued at about $26,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Immunome during the 1st quarter valued at about $80,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

Shares of Immunome stock opened at $17.38 on Monday. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -3.22 and a beta of 1.66. The firm’s 50-day moving average is $23.16 and its 200 day moving average is $14.80. Immunome has a 1 year low of $4.44 and a 1 year high of $30.96.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.